Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01184508 · ClinicalTrials.gov registry record · Phase 2
A Study in Migraine Prevention
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
NCT01184508 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 87 participants.
The verdict
NCT01184508, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
Study Summary
The primary objective of this study is to measure the change in frequency of migraine attacks per 28 days in migraine patients being treated orally with LY2300559 for 12 weeks.
Interventions
- DRUG Placebo
- DRUG LY2300559
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2011-01 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01184508
The ClinicalTrials.gov registry entry for NCT01184508 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01184508 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01184508 about?
NCT01184508 is a clinical study titled "A Study in Migraine Prevention". The primary objective of this study is to measure the change in frequency of migraine attacks per 28 days in migraine patients being treated orally with LY2300559 for 12 weeks.
What is the current status of trial NCT01184508?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2011-01. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01184508?
The interventions under investigation include: Placebo (DRUG), LY2300559 (DRUG).
Who is sponsoring clinical trial NCT01184508?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.